The HerediGENE Report

brca gene mutation

There are 3 types of Analysis Report.

Negative/Non-Pathogenic

A negative report indicates that no clinically significant mutation has been identified.

The report includes:

The Negative Result

Methodology

The Genes Analyzed

The Family Tree of the Patient

References

Positive/Pathogenic

A positive report indicates that a pathogenic mutation was identified. In this report you will find details about the variants detected and extensive interpretation of the risk of the individual, along with analysis of the findings.

The report includes:

The Positive Result

The Pathogenic Variants Identified

Variant details of the pathogenic variant and the gene

Methodology

The Genes Analyzed

The Family Tree of the Patient

References

VUS/Variant of Uncertain Significance

A VUS (Variant of Uncertain Clinical Significance) report indicates that the available data (published and in silico analysis) are not enough to characterize the variants identified as pathogenic or benign.

The report includes:

The VUS Result

VUS Identified

Variant Details of the VUS and the Gene

Methodology

The Genes Analyzed

The Family Tree of the Patient

 References

In these cases Genekor Laboratories follow up every month on new gene variations that are associated with cancer and update the database results of every individual test indefinitely to see if any of the VUS findings have been associated with cancer. In such rare case the laboratories inform the physician and the patient about the new finds, in order to proceed to personalized management.

brca gene mutation

The latest international guidelines (ASCO, ESMO, NCCN and American Society of Breast Surgeons) strongly recommend, instead of BRCA1/2 only, the use of multi-gene panels for a better coverage of the gene variants associated with an increased risk of breast, prostate, colon, pancreatic, ovarian cancer etc.